Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathologic Characteristics and Prognostic Factors in Patients with Operable HER-2 Overexpressing Breast Cancer

  • Liu, Ai-Na (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Sun, Ping (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Liu, Jian-Nan (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Ma, Jin-Bo (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Qu, Hua-Jun (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Zhu, Hua (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Yu, Cai-Yan (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine) ;
  • Zhang, Liang-Ming (Department of Medical Oncology, Yantai Yuhuangding Hospital and Affiliated Hospital of Qingdao University School of Medicine)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To study the relationship between clinical pathologic characteristics, treatment modalities and prognostic factors in HER-2 (Human Epidermal growth factor Receptor-2) overexpressed breast carcinoma. Materials and Methods: Major clinico-pathological factors including therapeutic modalities and survival status of 371 breast cancer patients with HER2 over-expression, teated at Yantai Yuhuangding Hospital from March of 2002 to December of 2010 were retrospectively studied, with special attention focused on survival-related factors. Results: The median age of the total 371 patients in this study was 48 years at time of diagnosis, among which, the leading pathological type was infiltrating ductal carcinoma (92.5%); 62.8% presented with a primary tomor larger than 2 cm in diameter at diagnosis, 51.0% had axillary lymph node (ALN) metastases; ER (Estrogen receptor)/PR (Progesterone receptor) double negative occured in 52.8% of cases, and PCNA (proliferation cell nuclear antigen) (+++) was found in 55.1%. HER-2 overexpressed patients were usually in advanced stage when the diagnosis was made (72.8% at stages IIA~IIIC). The prognosis and survival were assessed in 259 patients with complete follow-up data. 5-year DFS (disease-free survival) and OS (overall survival) rate was 68.0% and 78.0% respectively. Univariate analysis revealed that age, tumor size, ALN metastases, LVSI (lymph-vascular space involvement), PCNA status, hormonal therapy, chemotherapy cycles, and HER-2 overexpression, correlated closely with the prognosis. ALN metastases, LVSI, PCNA status and chemotherapy cycles were independent predictors of survival. Conclusions: HER-2 overexpressed breast cancer has special clinical and pathological characteristics, with advanced clinical stages and high rate of ER/PR double negative. Lymph node metastases, LVSI, PCNA and chemotherapy cycles are independent predictors of prognosis.

Keywords

References

  1. Aaltomaa S, Lipponen P, Syrjanen K (1993). Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res, 13, 533-8.
  2. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16. https://doi.org/10.1634/theoncologist.9-6-606
  3. Ellis MJ, Coop A, Singh B, et al (2001) . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol, 19, 3808-16.
  4. Faneyte IF, Peterse JL, Van Tinteren H, et al (2004) . Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res, 10, 4457-63. https://doi.org/10.1158/1078-0432.CCR-03-0054
  5. Ferrero-Pous M, Hacene K, Bouchet C, et al (2000) . Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res, 6, 4745-54.
  6. Fisher B, Bauer M, Wickerham DL, et al (1983) . Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer, 52, 1551-7. https://doi.org/10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
  7. Gianni L, Dafni U, Gelber RD, et al (2011) . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol, 12, 236-44. https://doi.org/10.1016/S1470-2045(11)70033-X
  8. Le Doussal V, Tubiana-Hulin M, Friedman S, et al (1989) . Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914-21. https://doi.org/10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G
  9. Menard S, Balsari A, Casalini P, et al (2002) . HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res, 8, 520-5.
  10. Moliterni A, Menard S, Valagussa P, et al (2003) . HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol, 21, 458-62. https://doi.org/10.1200/JCO.2003.04.021
  11. Romond EH, Perez EA, Bryant J, et al (2005) . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
  12. Nemoto T, Natarajan N, Bedwani R, et al (1983) . Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer, 51, 1333-8. https://doi.org/10.1002/1097-0142(19830415)51:8<1333::AID-CNCR2820510802>3.0.CO;2-T
  13. Neville AM, Bettelheim R, Gelber RD, et al (1992) . Factors predicting treatment responsiveness and prognosis in nodenegative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 696-705.
  14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005) . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72. https://doi.org/10.1056/NEJMoa052306
  15. Polychemotherapy for early breast cancer: an overview of the randomised trials (1998) . Early Breast Cancer Trialists' Collaborative Group. Lancet, 352, 930-42. https://doi.org/10.1016/S0140-6736(98)03301-7
  16. Revillion F, Bonneterre J, Peyrat JP (1998) . ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808. https://doi.org/10.1016/S0959-8049(97)10157-5
  17. Rosen PP, Groshen S, Saigo PE, et al (1989) . Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol, 7, 1239-51.
  18. Ross JS, Fletcher JA (1998) . The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist, 3, 237-52.
  19. Slamon DJ, Eiermann W, Robert N, et al (2005) . Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(ACTH) with docetaxel, carboplatin and trastuzumab(TCH) in her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res and Treat, 94, S5.
  20. Sledge GW Jr, Miller KD (2003) . Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer, 39, 1668-75. https://doi.org/10.1016/S0959-8049(03)00273-9
  21. Tahan SR, Neuberg DS, Dieffenbach A, et al (1993) . Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer, 71, 3552-9. https://doi.org/10.1002/1097-0142(19930601)71:11<3552::AID-CNCR2820711115>3.0.CO;2-N
  22. Tamoxifen for early breast cancer: an overview of the randomised trials (1998). Early Breast Cancer Trialists' Collaborative Group. Lancet, 351, 1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
  23. Tang ZY (2000). Contemporary Oncology 2nd Ed. Shanghai Medical University Press, 2000.
  24. Traina A, Agostara B, Marasa L, et al (2006) . HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci, 1089, 159-67. https://doi.org/10.1196/annals.1386.029
  25. Xia W, Chen JS, Zhou X, et al (2004). Phosphorylation/ cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res, 10, 3815-24. https://doi.org/10.1158/1078-0432.CCR-03-0527
  26. Yildirim E, Dalgic T, Berberoglu U (2000) . Prognostic significance of young age in breast cancer. J Surg Oncol, 74, 267-72. https://doi.org/10.1002/1096-9098(200008)74:4<267::AID-JSO5>3.0.CO;2-N

Cited by

  1. Predictive Factors for Supraclavicular Lymph Node Recurrence in N1 Breast Cancer Patients vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2509
  2. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER vol.110, pp.11, 2014, https://doi.org/10.1038/bjc.2014.174
  3. Benefit of Post-mastectomy Radiotherapy of the Supra-/infraclavicular Lymphatic Drainage Area in Breast Cancer Patients vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5557
  4. Relation of Alcohol/Tobacco use with Metastasis, Hormonal (Estrogen and Progesterone) Receptor Status and c-erbB2 Protein in Mammary Ductal Carcinoma vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5709
  5. SLC35B2 Expression is Associated with a Poor Prognosis of Invasive Ductal Breast Carcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6065
  6. Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6425
  7. Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3185
  8. Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2645
  9. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer vol.159, pp.2, 2016, https://doi.org/10.1007/s10549-016-3933-6